$OMER

Cancelmo Peter B sold $930K of OMER

Cancelmo Peter B (VP, General Counsel) sold 50,000 shares of OMEROS CORP (OMER) at an average of $18.59 ($18.54–$18.65, $0.93M total) across 2 trades over 2026-08-28 to 2026-08-31.

Original reporting
SEC EDGAR · Cancelmo Peter B
Published Sep 1, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Bearish
medium confidence
Mentioned
$OMER
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERBearishLow
01

Why it matters

The sale reduces insider ownership, which some investors view as a negative signal, though the amount is modest relative to market cap.

02

Market read

A routine insider sale with limited market impact.

03

What to watch

No 10b5-1 plan; the insider may have personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: filed post-market on Sep 1, 2026

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$OMERBearishMedium confidence
Context

VP and General Counsel Peter B. Cancelmo sold 50,000 shares for $929,667, reducing his stake to 200 shares.

Expected impact

Possible modest downward pressure in the near term.

Evidence & confidence

Large insider sell of ~0.5% of float, but no accompanying buyback or other catalyst.

Market effects

Minimal impact on the broader biotech sector.

Limited to US markets where OMER trades.

Low

Counterpoint

The sale could be unrelated to confidence, perhaps a tax or diversification move.

Key entities

  • Peter B. Cancelmo

    Vice President, General Counsel of OMEROS CORP

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMERHighAI 8/10

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

$OMERMed

OMEROS CORP (OMER): Results of Operations and Financial Condition

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q

$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.